SPC2996 in Chronic Lymphocytic Leukaemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 30, 2005

Study Completion Date

December 31, 2007

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

SPC2996

Trial Locations (12)

2100

Rigshospitalet, Copenhagen

2730

KAS Herlev, Herlev

7100

Vejle Sygehus, Vejle

52242

Holden Comprehensive Cancer Center, Univ. of Iowa, Iowa City

59037

Bruno Cazin, Lille

69437

Mauricette Michellet, Lyon

69495

Service d'HématologieCentre Hospitalier Lyon-Syd, Lyon

76038

Centre Henri Becquerel, Rouen

LS1 3EX

Leeds General Infirmary, Leeds

LE1 9HN

MRC Toxicology Unit, University of Leicester, Leicester

M20 4BX

Christie Hospital NHS Trust, Manchester

SM2 5PT

The Royal Marsden NHS Foundation Trust, Surrey

All Listed Sponsors
lead

Santaris Pharma A/S

INDUSTRY

NCT00285103 - SPC2996 in Chronic Lymphocytic Leukaemia | Biotech Hunter | Biotech Hunter